Recent Company News

• 08:01 AM ET Jun 02, 2025
  

  AstraZeneca and Daiichi Sankyo's ENHERTU plus pertuzumab showed a median progression-free survival greater than three years (10642.0000p, -78)

• 09:09 AM ET Jun 01, 2025
  

  Daiichi Sankyo presents positive results from three trials of DATROWAY in patients with early and advanced non-small cell lung cancer (¥3842.0000, 0)

• 05:11 AM ET Jun 01, 2025
  

  Daiichi Sankyo announces positive results from DESTINY-Gastric04 phase 3 trial of ENHERTU as second-Line therapy in patients with HER2 positive unresectable or metastatic gastric cancer (¥3842.0000, 0)

• 04:46 PM ET May 29, 2025
  

  StreetAccount Sector Summary - Healthcare Post-Market

• 08:56 AM ET May 29, 2025
  

  StreetAccount Sector Summary - Healthcare Pre-Market

• 07:10 AM ET May 29, 2025
  

  Daiichi Sankyo, Merck voluntarily withdraw BLA for patritumab deruxtecan for patients with previously treated locally advanced or metastatic EGFR-mutated NSCLC (¥3894.0000, 0)

• 08:06 AM ET May 23, 2025
  

  AstraZeneca's ENHERTU (trastuzumab deruxtecan) receives time-limited reimbursement recommendation from Canada's Drug Agency for gastric cancer (10358.0000p, -16)

• 03:17 AM ET May 22, 2025
  

  NTK files motion to expand claims in lawsuit for compensation for damages against Daiichi Sankyo (¥3753.0000, 0)

• 07:05 AM ET May 19, 2025
  

  Daiichi Sankyo doses first patient in phase III trial of ifinatamab deruxtecan for treatment of pretreated advanced or metastatic esophageal squamous cell carcinoma (¥3698.0000, 0)

• 11:28 PM ET May 18, 2025
  

  StreetAccount Summary - Trading higher/lower: Asia mid-morning